SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960–1993: is the epidemiology changing? Arthritis Rheum 1996; 39: 138590.
  • 2
    Ruperto N, Levinson JE, Ravelli A, Shear ES, Tague BL, Murray K, et al. Longterm health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol 1997; 24: 94551.
  • 3
    Hull RG, and the British Paediatric Rheumatology Group. Guidelines for management of childhood arthritis. Rheumatology (Oxford) 2001; 40: 130912.
  • 4
    Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002; 109: 10915.
  • 5
    Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35 Suppl 1: 6877.
  • 6
    Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999; 107: 4854S.
  • 7
    Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003; 42: 133241.
  • 8
    Foeldvari I, Burgos-Vargas R, Thon A, Tuerck D. High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol 2002; 29: 107983.
  • 9
    Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritides, Durban, 1997. J Rheumatol 1998; 25: 19914.
  • 10
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 12029.
  • 11
    Ruperto N, Ravelli A, Falcini F, Lepore L, de Sanctis R, Zulian F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998; 57: 3841.
  • 12
    Albornoz MA. ACR formally adopts improvement criteria for juvenile arthritis (ACR pediatric 30). ACR News 2002; 21: 3.
  • 13
    Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ Jr, Fink CW, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29: 27481.
  • 14
    Ruperto N, Giannini EH. Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Ann Rheum Dis 1996; 55: 735.
  • 15
    Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 17619.
  • 16
    Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001; 19(4 Suppl 23 ): S19.
  • 17
    Huemer C, Ruperto N, Huemer M, Sailer-Hoeck M, Kaulfersch W, Schwarz R, et al. The Austrian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19:(4 Suppl 23 ): S159.
  • 18
    Joos R, Ruperto N, Wouters C, Boven K, Raat H, Landgraf JM, et al. The Belgian-Flemish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19(4 Suppl 23 ): S204.
  • 19
    Pouchot J, Ruperto N, Lemelle I, Sommelet D, Grouteau E, David L, et al. The French version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19: S605.
  • 20
    Foeldvari I, Ruperto N, Dressler F, Hafner R, Kuster RM, Michels H, et al. The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19(4 Suppl 23 ): S715.
  • 21
    Ruperto N, Ravelli A, Pistorio A, Malattia C, Viola S, Cavuto S, et al. The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19(4 Suppl 23 ): S915.
  • 22
    Nikishina O, Ruperto N, Kuzmina N, Shelepina T, Illarionova O, Salougina S, et al. The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19(4 Suppl 23 ): S1315.
  • 23
    Nugent J, Ruperto N, Grainger J, Machado C, Sawhney S, Baildam E, et al. The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19: S1637.
  • 24
    McGrath PA, Seifert CE, Speechley KN, Booth JC, Stitt L, Gibson MC. A new analogue scale for assessing children's pain: an initial validation study. Pain 1996; 64: 43543.
  • 25
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 11914.
  • 26
    Brown EG. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 2003; 26: 14558.
  • 27
    Committee on Drugs, American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric population. Pediatrics 1995; 95: 28694.
  • 28
    Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biologic products in pediatrics patients. Federal Register 1998; 63: 6663172.
  • 29
    European Medicines Evaluation Agency. Report on the experts round table on the difficulties related to the use of new medicinal products in children held on 18 December 1997. EMEA, 1998. (27164/98 Rev. 1.)
  • 30
    Ruperto N, Pistorio A, Martini A, Sigmund R, Hanft G, Simianer S. A meta-analysis to estimate the “real” placebo effect in juvenile rheumatoid arthritis (JRA) trials [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S90.
  • 31
    Cassidy JT, Petty RE. Juvenile rheumatoid arthritis. In: CassidyJT, PettyRE, editors. Textbook of pediatric rheumatology. 4th ed. Philadelphia: WB Saunders; 2001. p. 218322.
  • 32
    Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis: assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand J Rheumatol 1984; 13: 34250.
  • 33
    Leak AM, Richter MR, Clemens LE, Hall MA, Ansell BM. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 15760.
  • 34
    Makela AL. Naproxen in the treatment of juvenile rheumatoid arthritis: metabolism, safety and efficacy. Scand J Rheumatol 1977; 6: 193205.
  • 35
    Williams PL, Ansell BM, Bell A, Cain AR, Chamberlain MA, Clarke AK, et al. Multicentre study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood. Br J Rheumatol 1986; 25: 6771.
  • 36
    Laxer RM, Silverman ED, St-Cyr C, Tran MT, Lingam G. A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis. Clin Ther 1988; 10: 3817.
  • 37
    Physicians' Desk Reference. Montvale (NJ): Medical Economics; 2001.
  • 38
    Keenan GF, Giannini EH, Athreya BH. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol 1995; 22: 114951.